2月4日,艾伯维(AbbVie)公布2025年第四季度及全年业绩,营收和盈利均超预期。免疫板块表现不一:Humira超预期贡献大部分增长,Skyrizi强劲增长,Rinvoq略低于预期。公司股价当天下跌约4%,投资者对Humira衰退期公司增长仍依赖该药表示担忧。艾伯维第四季度销售额超出预期约2亿美元,这主要得益于其重磅药物Humira(阿达木单抗)的出色表现,而其后续免疫学药物Rinvoq(...
Source Link2月4日,艾伯维(AbbVie)公布2025年第四季度及全年业绩,营收和盈利均超预期。免疫板块表现不一:Humira超预期贡献大部分增长,Skyrizi强劲增长,Rinvoq略低于预期。公司股价当天下跌约4%,投资者对Humira衰退期公司增长仍依赖该药表示担忧。艾伯维第四季度销售额超出预期约2亿美元,这主要得益于其重磅药物Humira(阿达木单抗)的出色表现,而其后续免疫学药物Rinvoq(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.